Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the radiotherapeutic treatment of lung cancer, the dose that can be safely applied to the tumour is limited by the risk of radiation induced lung damage. This damage is characterized by parenchymal damage and vascular damage. In rats, we have found that radiation-induced vascular damage results in increased pulmonary artery pressure. Interestingly, the consequent loss of pulmonary function could be fully explained by this increase in pulmonary artery pressure. We hypothesize that also in patients a radiation induced increase in pulmonary artery pressure can be observed after radiotherapy, which may contribute to the development of radiation pneumonitis.

The objective is to test the hypothesis that radiotherapy for lung cancer induces an increase in pulmonary artery pressure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

NCT04901884

Pulmonary Hypertension

RECRUITING NA

Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers

NCT01421953

Lung Cancer Non-small-cell Lung Carcinoma

COMPLETED NA

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection

NCT03417687

Pulmonary Surgical Procedures

COMPLETED PHASE3

MRI Optimization Study in Stage III NSCLC

NCT02076282

Stage III Non-small Cell Lung Cancer

UNKNOWN

PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents

NCT02325349

Advanced Head and Neck Carcinoma Advanced Non-small Cell Lung Carcinoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac Magnetic Resonance Imaging (MRI)

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* WHO PS 0-2
* Histological or cytological confirmation of non-small cell lung cancer or an 18F-FDG-positive, growing mass on CT-thorax suggestive of NSCLC.
* Stage IIIA or IIIB
* Patients with extensive mediastinal lymph node involvement (such as N3), or large primary tumour size
* Adequate pulmonary function estimated by flow volume curves
* Life expectancy of at least 6 months
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial.
* Planned for 25 x 2.4 Gy, with concomitant chemotherapy
* Before patient registration, written informed consent will be obtained.